Ads
related to: contagion
Search results
Jacob Rees-Mogg claims UK government 'downplayed' risks of AstraZeneca COVID vaccine
Yahoo News UK· 1 day agoRees-Mogg suggested that a major problem was that the nature of the rollout had encouraged...
To Address the Mental Health Crisis, Look to School Nurses
Time Magazine· 4 days agoThere are already people on the front lines to combat this teen mental health crisis: school nurses,...
Destiny 2: The Final Shape Is Changing How Some Of Its Bounties Work
Kotaku· 23 hours agoDestiny bounty preppers are shaking in their boots
Bank of Canada warns bets tied to timing of rate cuts are boosting leverage in some markets
Financial Post via Yahoo Finance· 1 day agoRogers noted that banks, pensions, hedge funds and investment dealers involved in Canada’s financial...
Wealthcare Advisory Partners LLC Invests $207,000 in Invesco PHLX Semiconductor ETF (NASDAQ:SOXQ)
ETF DAILY NEWS· 11 hours agoWealthcare Advisory Partners LLC acquired a new position in Invesco PHLX Semiconductor ETF (NASDAQ:SOXQ – Free Report) in the fourth quarter, according to the company in its most recent filing ...
Workers at Apple stores are pushing to join unions
Orange County Register· 21 hours agoNow, its leaders also have to contend with labor unrest. Apple store workers in Towson, Maryland, made history in June 2022 when they voted to form the...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $50.80 Average Target Price from Brokerages
ETF DAILY NEWS· 14 hours agoArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eleven brokerages that are presently covering the stock, MarketBeat.com ...
Why Remote Work Is Incompatible With A Company's Long Term Growth
Forbes· 4 days agoTech giants around the globe are pushing or pulling employees to return to the office. Strategies...
Analysts Set Insulet Co. (NASDAQ:PODD) Price Target at $240.33
ETF DAILY NEWS· 16 hours agoInsulet Co. (NASDAQ:PODD – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seventeen research firms that are currently covering the company, Marketbeat.com reports ...
Leerink Partnrs Weighs in on Pliant Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:PLRX)
ETF DAILY NEWS· 17 hours agoPliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) – Leerink Partnrs raised their Q2 2024 earnings per share (EPS) estimates for Pliant Therapeutics in a research note issued to investors ...